Depression and anxiety affects levels of function across different levels like work, increasing levels of sick leave and as well as cognitive functioning. In the current study patients at risk of sick leave with depression and anxiety receive metacognitive therapy and work focus in an ordinary outpatient clinic. Impaired cognitive functioning may also be of importance in the return to work process and degree of sick leave. It is important to get a better understanding of how cognitive functioning is related to sick leave and if it predicts return to work, and if cognitive functioning is changed due to psychological treatment.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* diagnosis of depression and/or anxiety,
* at risk of sick leave
Exclusion Criteria:
* personality disorders cluster A or B,
* ongoing substance abuse,
* symptoms of psychosis,
* acute suicidality,
* serious somatic disorders
Primary outcome measure(s)
Patient Health Questionnaire-9 (PHQ-9) — Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-up Measure of depressive symptoms (PHQ-9) range 0-27 higher scores indicate higher degree of depressive symptoms
Generalized Anxiety Disorder (GAD-7) — Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-up Anxiety symptoms (GAD-7) range 0-21 higher scores indicating higher degree of anxiety symptoms
Changes in sick leave — Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-up Sick leave is collected from national register data measured in number of days of sick leave.
Trial sites (1)
Facility
City
Region
Status
Diakonhjemmet hospital
Oslo
Norway
Recruiting
More Norwegian University of Science and Technology trials in Norway
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.